---
title: "ABBISKO-B presented long-term efficacy and safety data from the Phase III MANEUVER study of pimasertib at the 2025 ESMO conference"
description: "ABBISKO-B presented long-term efficacy and safety data from its global Phase III MANEUVER study of pimasertib in patients with tenosynovial giant cell tumors (TGCT) at the 2025 ESMO conference. The st"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261787363.md"
published_at: "2025-10-20T00:34:02.000Z"
---

# ABBISKO-B presented long-term efficacy and safety data from the Phase III MANEUVER study of pimasertib at the 2025 ESMO conference

> ABBISKO-B presented long-term efficacy and safety data from its global Phase III MANEUVER study of pimasertib in patients with tenosynovial giant cell tumors (TGCT) at the 2025 ESMO conference. The study showed that pimasertib demonstrated strong and durable tumor response, with an objective response rate (ORR) of 54%, compared to only 3.2% in the placebo group. The safety profile of the drug was consistent with previous analyses, confirming the feasibility of long-term treatment

According to the Zhitong Finance APP, HeYu-B (02256) announced that its subsidiary Shanghai HeYu Biopharmaceutical Technology Co., Ltd. (HeYu Pharmaceuticals) has presented the long-term efficacy and safety data of its global Phase III MANEUVER study of pimicotinib (pimicotinib/ABSK021) for the treatment of patients with tenosynovial giant cell tumor (TGCT) in an oral presentation at the 2025 European Society for Medical Oncology (ESMO) annual meeting. This long-term analysis shows that the objective response rate (ORR) assessed by the blinded independent review committee (BIRC) according to RECIST v1.1 criteria and tumor volume score (TVS) confirms that pimicotinib demonstrates strong and durable tumor response efficacy, with clinical outcome assessments (including joint mobility, stiffness, pain, and physical function) showing clinically meaningful sustained improvements, and safety consistent with previous analyses, validating the feasibility of long-term treatment.

TGCT is a rare locally aggressive mesenchymal tumor primarily affecting joints, tendon sheaths, and bursae, which can lead to severe local lesions and functional impairment. Its mechanism of occurrence is the overexpression of colony-stimulating factor 1 (CSF-1) in tumor synovial cells, leading to the accumulation of inflammatory cells expressing colony-stimulating factor 1 receptor (CSF-1R) in the tumor.

Pimicotinib is a novel, orally administered, highly selective, and effective small molecule CSF-1R inhibitor independently developed by HeYu Pharmaceuticals. The global Phase III MANEUVER study consists of three parts and aims to evaluate the efficacy and safety of pimicotinib in patients with TGCT. The results of the first part of the MANEUVER study, announced at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, showed that pimicotinib provided significant efficacy benefits for patients: at week 25, the ORR in the pimicotinib treatment group assessed by BIRC according to RECIST v1.1 criteria reached 54%, while the placebo control group was only 3.2%.

At the 2025 ESMO meeting, the principal investigator (PI) of the MANEUVER study, Professor Niu Xiaohui from Beijing Jishuitan Hospital, reported the long-term efficacy and safety data: at a median follow-up of 14.3 months, the ORR in patients randomly assigned to receive pimicotinib in the first part, assessed by BIRC according to RECIST v1.1 criteria, increased to 76.2% (95% CI: 63.8, 86.0), with the median duration of response (mDOR) not yet reached (range: 0.03-19.81 months); at the end of the second part (week 49), clinical outcome assessments continued to improve and safety was good, with pimicotinib showing a relative improvement in joint mobility of 23.9% compared to baseline by week 73. Patients who were randomly assigned to receive placebo in the first part also benefited after switching to pimicotinib in the second part, with ORR assessed by BIRC according to RECIST v1.1 criteria and TVS both reaching 64.5%, and clinical outcome assessments also showed improvement.

As more data confirms the efficacy, safety, and tolerability of pimicotinib in the long-term treatment of TGCT, its potential and commercial value as a best-in-class treatment option will gradually be realized Pimicotinib is a new, oral, highly selective, and efficient small molecule CSF-1R inhibitor independently developed by ABBISKO. Its positive top-line results for TGCT in the global Phase III MANEUVER study were published in November 2024. Currently, Pimicotinib has been included in priority review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment. Pimicotinib has also received Breakthrough Therapy Designation (BTD) from the NMPA. In December 2023, ABBISKO reached an agreement with Merck & Co. for the commercialization rights of Pimicotinib, with Merck responsible for its global commercialization.

In overseas regions, Pimicotinib has also received BTD from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA)

### Related Stocks

- [02256.HK - ABBISKO-B](https://longbridge.com/en/quote/02256.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 和誉-B 推进 FGFR4 抑制剂 Irpagratinib，全球肝细胞癌试验中首位美国患者已接受剂量 | Abbisko Cayman Limited 已经在一项全球 I 期临床试验中为首位美国患者注射了 irpagratinib，这是一种针对晚期肝细胞癌的 FGFR4 抑制剂。该药物已获得美国 FDA 的快速通道认证，并在中国获得突破性疗法认 | [Link](https://longbridge.com/en/news/275528457.md) |
| 特斯拉首辆 Cybercab 下线：没有方向盘和踏板的汽车终于来了 | 特斯拉宣布，首辆赛博无人驾驶电动车 Tesla Cybercab 在美国得州超级工厂正式下线。风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、 | [Link](https://longbridge.com/en/news/276188665.md) |
| 别为美最高法推翻特朗普关税高兴太早？华尔街预计市场反应或昙花一现 | 美国股债汇波动相对温和的一个重要原因是，预测市场此前已倾向于这一裁决结果，且特朗普随后表示已有备用方案。虽然特朗普至少有五种替代的法律工具重新征收关税，但无论采取何种方式，都将对长期美债的收益率构成上行压力。 | [Link](https://longbridge.com/en/news/276487370.md) |
| 对于伊朗和油价，特朗普是 “自信过头” 还是 “姿态做足”？ | 彭博专栏作者哈维尔·布拉斯表示，白宫不应仅凭去年轰炸伊朗未引发油价飙升，就断定未来军事行动不会冲击能源市场。尽管美国能源部长赖特将油价平稳归功于 “能源主导议程” 与创纪录产量，但市场韧性不等于免疫。若美方误判伊朗以石油为武器的反击底线，中 | [Link](https://longbridge.com/en/news/276327905.md) |
| 数字黄金、未来支付、投机之选？比特币的 “叙事” 在 “信仰巅峰” 逐个崩塌 | 赋予比特币引力的故事——数字黄金、自由货币、投机功能正在同时瓦解，代币化、区块链驱动的衍生品和跨境稳定币支付正在成为可信的用例，而这些都不需要比特币参与。同时，黄金和白银今年上演了波动性反弹，而加密货币只是下跌。此外，比特币对投机文化的掌控 | [Link](https://longbridge.com/en/news/276523166.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.